Glooko and Mylife Diabetes Care Expand Diabetes Data Management Partnership

Why It Matters

Unified data management reduces friction for providers, accelerating adoption of automated insulin delivery and potentially lowering glycemic risk across the diabetes ecosystem.

Key Takeaways

• Glooko named primary data platform for mylife Loop and CamAPS FX.
• Partnership expands to all mylife products, enhancing clinic data access.
• Integrated data aims to improve glycemic safety and clinical workflow.
• Supports growing automated insulin delivery market with seamless data sharing.
• Patients urged to connect via providers for Glooko onboarding support.

Pulse Analysis

The diabetes technology landscape is rapidly converging on cloud‑based platforms that aggregate data from pumps, continuous glucose monitors, and smart pens. As automated insulin delivery (AID) systems become standard of care, clinicians demand a single source of truth to interpret trends and adjust therapy. Glooko, already entrenched in many health systems, offers a scalable solution that meets regulatory requirements for data security while providing actionable insights at the point of care.

By appointing Glooko as the default data hub for mylife’s Loop and CamAPS FX devices, the two firms eliminate the need for patients to juggle multiple apps or manual uploads. This seamless flow of real‑time glucose, insulin dosing, and device alerts enables endocrinologists to intervene earlier, reducing episodes of hypoglycemia and hyperglycemia. The partnership also leverages Glooko’s analytics engine, which can flag risk patterns across large patient cohorts, supporting both individualized treatment plans and population‑level quality initiatives.

The broader market implication is a push toward interoperable ecosystems where device manufacturers align with established health‑IT platforms rather than building proprietary data silos. As payers increasingly tie reimbursement to outcomes, integrated data solutions become a competitive differentiator. For patients, the promise is a smoother onboarding experience and fewer barriers to adopting advanced AID therapy, ultimately driving better disease control and quality of life.